The doctor-dope drought has broken. Last year, news outlets reported that medicinal cannabis was “pretty much inaccessible”. In May, The New Daily reported on a study that found…
Two indices tracking the performance of cannabis companies on North America’s largest stock exchanges have launched in recent months, demonstrating a growing level of mainstream interest…
Prohibition Partners is proud to present Disrupting Beauty, the first report in our ‘Impact Series’ showcasing how cannabis is permeating the mainstream. Disrupting Beauty documents how…
The Israeli medical cannabis industry had expected 2019 to be a pivotal year. Planned regulatory milestones caused a slew of former politicians and public figures to…
The battered cannabis industry is starting to come to life. The bear market killed the hype. One analyst predicts it’s poised for a resurgence. The badly…
Great data-driven, powerful visuals to keep millions of people around the world ahead of the curve. The Big Pharma takeover of medical cannabis … a little easier…
A popular cannabis-derived epilepsy treatment is increasing sales for a London company making pharmaceutical treatments from marijuana. London-based GW Pharmaceuticals told investors Monday that it rang up $108 million…
International holdings becoming burden to companies needing to divest non-core assets Two years ago, Canadian cannabis companies were racing to scoop up international assets, from swaths…
The cannabis market on track to reach $43 billion in 2024. Global cannabis sales rose 48% to $15 billion in 2019, driven by growth in sales in…
It wasn’t long ago that cultivating hemp anywhere in the United States landed farmers in jail. Times obviously have changed. Drive along rural roads in many…